Welcome to our dedicated page for TRxADE HEALTH news (Ticker: MEDS), a resource for investors and traders seeking the latest updates and insights on TRxADE HEALTH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRxADE HEALTH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRxADE HEALTH's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TRxADE HEALTH INC. (NASDAQ:MEDS) will release its financial results for the first quarter of 2023 on May 8, 2023, after market close. The results will be discussed in a conference call at 5:00 p.m. Eastern time on the same day. Interested participants can join via a toll-free U.S. number or an international dial-in. TRxADE focuses on optimizing the retail pharmacy experience, utilizing technology to enhance drug procurement and patient engagement. The company serves over 14,500 members, promoting price transparency and offering telehealth services under the Bonum Health brand. A playback of the conference call will be accessible until June 8, 2023, providing further insights into the company's financial performance.
TRxADE Health, a digital healthcare services IT company, reported a 16% revenue increase to $11.4 million for the fiscal year 2022, up from $9.9 million in 2021. Key growth drivers included a 10% increase in revenues from the TRxADE Platform and a 46% rise from Trxade Prime, despite a 29% revenue decline in its Community Specialty Pharmacy unit. The firm's gross profit remained steady at 48%, and net losses narrowed to $3.9 million, down from $5.3 million in 2021. The company expanded its registered users by 8%, totaling over 14,400. A conference call is scheduled for March 27, 2023, to discuss these results.